Agenus Inc (AGEN)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

アジーナス、「ESMO GI 2026」で活動性肝転移を伴わない難治性MSS転移性大腸がんにおける3年時点の全生存率33%を示す画期的なBOT+BALデータを発表

患者登録が完了した123例の第1b相コホートで、全生存期間中央値21.2か月、3年時点の全生存率33%、および2年を超える時点での生存曲線のプラトーを示す 持続...

Agenus präsentiert auf der ESMO GI 2026 bahnbrechende BOT+BAL-Daten, die ein dreijähriges Gesamtüberleben von 33 % bei refraktärem MSS-metastasiertem Kolorektalkarzinom ohne aktive Lebermetastasen belegen

Die vollständig rekrutierte Phase-1b-Kohorte mit 123 Patienten zeigte eine mediane Gesamtüberlebenszeit von 21,2 Monaten, eine...

Form 8-K - Current report

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% three-year overall survival, and a survival...

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b study Agenus Inc. (Nasdaq: AGEN), a leader in...

Form 8-K - Current report

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at...

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had...

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy Median overall...

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material